AARTI DRUGS LTD. Fair Value
AARTIDRUGS · Healthcare · Current price ₹426.8
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹185 | 13% ROE fading to 12% over ~10 yrs, on ₹170 book |
| Relative P/E | ₹648 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹286 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹474 | Street consensus 12-month target price |
Is AARTI DRUGS LTD. undervalued?
DocStoX estimates the fair value of AARTI DRUGS LTD. at ₹357 per share, versus the current market price of ₹427. That puts the stock about -16.4% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹185), Relative P/E (₹648), Graham floor (₹286), Analyst target (₹474). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹185 (bear) to ₹357 (base) to ₹648 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on AARTI DRUGS LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.